ZA945005B - Heparin derivatives having antimetastatic activity - Google Patents

Heparin derivatives having antimetastatic activity

Info

Publication number
ZA945005B
ZA945005B ZA945005A ZA945005A ZA945005B ZA 945005 B ZA945005 B ZA 945005B ZA 945005 A ZA945005 A ZA 945005A ZA 945005 A ZA945005 A ZA 945005A ZA 945005 B ZA945005 B ZA 945005B
Authority
ZA
South Africa
Prior art keywords
heparin derivatives
daltons
antimetastatic activity
acylated
molecular weights
Prior art date
Application number
ZA945005A
Other languages
English (en)
Inventor
Patrizia Caretto
Teresa Sciumbata
Flavio Leoni
Gianni Gromo
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of ZA945005B publication Critical patent/ZA945005B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA945005A 1993-07-12 1994-07-11 Heparin derivatives having antimetastatic activity ZA945005B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT93MI001518A IT1264709B1 (it) 1993-07-12 1993-07-12 Derivati eparinici ad attivita' antimetastatica

Publications (1)

Publication Number Publication Date
ZA945005B true ZA945005B (en) 1995-02-21

Family

ID=11366579

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA945005A ZA945005B (en) 1993-07-12 1994-07-11 Heparin derivatives having antimetastatic activity

Country Status (15)

Country Link
US (2) US5763421A (de)
EP (1) EP0708785B1 (de)
JP (1) JPH08512353A (de)
AT (1) ATE177433T1 (de)
AU (1) AU7345194A (de)
CA (1) CA2167059A1 (de)
DE (1) DE69417035T2 (de)
DK (1) DK0708785T3 (de)
ES (1) ES2128573T3 (de)
FI (1) FI960130A7 (de)
GR (1) GR3029861T3 (de)
IL (1) IL110287A0 (de)
IT (1) IT1264709B1 (de)
WO (1) WO1995002613A2 (de)
ZA (1) ZA945005B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
JP2003504428A (ja) * 1999-06-30 2003-02-04 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド クロット関連凝固因子を阻害するヘパリン組成物
US6641571B2 (en) 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
AU2001291549A1 (en) * 2000-09-08 2002-03-22 Hamilton Civic Hospitals Research Development Inc. Antithrombotic compositions
CZ307433B6 (cs) * 2001-09-12 2018-08-22 Leadiant Biosciences Sa Deriváty částečně desulfátovaných glykosaminoglykanů jako inhibitory heparanázy mající antiangiogenní účinky a zabraňující antikoagulačnímu působení
EP1518120A4 (de) 2002-03-11 2008-08-13 Momenta Pharmaceuticals Inc Analyse sulfatierter polysaccharide
WO2005089365A2 (en) * 2004-03-16 2005-09-29 The General Hospital Corporation Treatment and prevention of abnormal cellular proliferation
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) * 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2817779T3 (es) * 2010-01-19 2021-04-08 Momenta Pharmaceuticals Inc Evaluación de preparaciones de heparina
CN102985443B (zh) 2010-04-16 2017-05-10 动量制药公司 组织靶向
CA2795868A1 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
JP6132302B2 (ja) * 2013-05-28 2017-05-24 リーディアント・バイオサイエンシーズ・ソシエタ・アノニマＬｅａｄｉａｎｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｓ．Ａ． 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
JP2016520613A (ja) 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド 薬学的組成物
JP2016014148A (ja) * 2015-09-10 2016-01-28 シグマ−タウ・リサーチ・スウィッツァーランド・ソシエテ・アノニム 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1987M (fr) * 1961-08-01 1963-08-26 Evans Medical Ltd Médicament antilipémique a base d'héparine modifiée.
US3118816A (en) * 1962-04-03 1964-01-21 Abbott Lab N-succinyl heparin and process
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
DE3422518A1 (de) * 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
US5541166A (en) * 1987-01-23 1996-07-30 The Australian National University Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
IT1230582B (it) * 1988-10-21 1991-10-28 Opocrin S P A Lab Farmabiologi Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
CA2157388C (en) * 1993-03-01 1998-12-15 Daniel P. Witt Analogs for specific oligosaccharide-protein interactions and uses thereof

Also Published As

Publication number Publication date
AU7345194A (en) 1995-02-13
ES2128573T3 (es) 1999-05-16
DE69417035T2 (de) 1999-08-05
EP0708785B1 (de) 1999-03-10
ITMI931518A0 (it) 1993-07-12
WO1995002613A2 (en) 1995-01-26
DE69417035D1 (de) 1999-04-15
US6130210A (en) 2000-10-10
JPH08512353A (ja) 1996-12-24
ITMI931518A1 (it) 1995-01-12
DK0708785T3 (da) 1999-10-04
US5763421A (en) 1998-06-09
IT1264709B1 (it) 1996-10-04
WO1995002613A3 (en) 1995-03-09
ATE177433T1 (de) 1999-03-15
EP0708785A1 (de) 1996-05-01
IL110287A0 (en) 1994-10-21
FI960130L (fi) 1996-01-11
FI960130A0 (fi) 1996-01-11
FI960130A7 (fi) 1996-01-11
CA2167059A1 (en) 1995-01-26
GR3029861T3 (en) 1999-07-30

Similar Documents

Publication Publication Date Title
GR3029861T3 (en) Heparin derivatives having antimetastatic activity
NZ287335A (en) Copolymer-1 composition substantially free of species of copolymer -1 with a mw of from 4 kda to 8 kda, in particular 6.25 kda to 8.4 kda
CA2011171A1 (en) Biodegradable Poly (Phosphate Esters)
DE68924398D1 (de) Metall-Polymer-Zusammensetzungen.
AU5062199A (en) Suppository formulations comprising anionic polysaccharide
WO1993009156A3 (en) Superior stain resistant compositions
ES466246A1 (es) Procedimiento para la obtencion de copolieteresteramidas es-tables a la hidrolisis.
ATE148346T1 (de) Antiproliferative oligomere
PT1017403E (pt) Utilizacao de hialuronato de zinco contra a ulcera peptica
ATE187177T1 (de) Verzweigtes polysaccharide, es produzierender mikroorganismus und zusammensetzungen welche sie enthalten
IL107736A0 (en) Triphostins and pharmaceutical compositions containing them
FR2680317B1 (fr) Composition vegetale de bas poids moleculaire.
ITTO930610A1 (it) Composizione a base di 1, 1, 1, 3, 3, -pentafluorobutano e di cloruro di metilene per la pulitura e/o essicazione di superfici solide.
NO950602L (no) Antiangiogeniske oligomerer
DK0444482T3 (da) Oxetanoner
HU9600297D0 (en) Rye-flour
ATE122874T1 (de) Antischuppenmittel.
DE68918618D1 (de) Polymerisationsverfahren und daraus erhaltene Produkte.
DE68916200D1 (de) Rost- und korrosionsverhindernde Zusammensetzungen.
ATE147944T1 (de) Huminate enthaltende diätetika
EP0189877A3 (de) Triazinringe oder Estergruppen enthaltende verhinderte 2-Keto-1,4-diazazykloalkanoligomere und mit diesen stabilisierte Zusammensetzungen
DE69102932D1 (de) Verfahren zur Verhinderung von Niederschlägen in Silikonzusammensetzungen.
WO2000029433A3 (en) 12-25-kda bacterial proteins and their 116-58 kda polymers for use e.g. in anti-tumor vaccines
ATE78694T1 (de) Methoden und praeparate zur vorbeugung von ulcera.
IT8711578V0 (it) Portaoggetti da tavola in metallo od altro,con sistemi di componibilita' di elementi utili,singolarmente,uniti fra loro.